Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parneet K Cheema

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Oncology Practice|December 29, 2016
Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerParneet K Cheema, Ines B Menjak, Zoe Winterton-Perks, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung CancerDiana N Ionescu, Tracy L Stockley, Shantanu Banerji, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLCParneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario ForumParneet K Cheema, Paul F Wheatley-Price, Matthew J Cecchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung CancerDavid Planchard, Michael J Boyer, Jong-Seok Lee, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung CancerBarbara L Melosky, Natasha B Leighl, David Dawe, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community CentreParneet K Cheema, Marco A J Iafolla, Massey Nematollahi, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLCParneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
JTO Clinical and Research Reports|June 26, 2025
Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer ManagementKassandra R Bisson, Andrea Beharry, Normand Blais, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Oncology Practice|December 29, 2016
Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerParneet K Cheema, Ines B Menjak, Zoe Winterton-Perks, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung CancerDiana N Ionescu, Tracy L Stockley, Shantanu Banerji, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLCParneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario ForumParneet K Cheema, Paul F Wheatley-Price, Matthew J Cecchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung CancerDavid Planchard, Michael J Boyer, Jong-Seok Lee, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung CancerBarbara L Melosky, Natasha B Leighl, David Dawe, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community CentreParneet K Cheema, Marco A J Iafolla, Massey Nematollahi, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLCParneet K Cheema, Shantanu O Banerji, Normand Blais, et al.
JTO Clinical and Research Reports|June 26, 2025
Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer ManagementKassandra R Bisson, Andrea Beharry, Normand Blais, et al.
Pageof 3